Novel next-generation polymerase chain reaction (PCR) reagents engineered for clinical diagnostics have rapidly increased the scope and usage of PCR reagents for pathogen and disease detection.
New analysis from Frost & Sullivan (drugdiscovery.frost.com), European PCR Reagent Market for Research Applications and Clinical Diagnostics, finds that the market earned revenue of $883 million in 2010 and estimates this to reach $1600.1 million in 2017. The research covers PCR reagents being used and supplied for clinical diagnostics, research application and applied testing sectors.
Significant market growth, since 2007, can be attributed to the patent expiry of Taq polymerase. With its expiry, PCR reagents have been made available for more common use, increasing consumption levels.
"There is rising demand for PCR reagents in diagnostic testing for pathogen detection," notes Frost & Sullivan Research Analyst Divyaa Ravishankar. "Innovative product features are, moreover, expanding the customer base, resulting in higher revenue generation."
Clinicians are utilising PCR to conduct routine medical diagnostic tests and reveal important information such as the identification of biomarkers. This may reveal the early signs of development of cancer, tumours, heart disease and many more.
In the area of life sciences research, PCR reagents are being deployed in human disease research, genetic analysis, pharmaceutical drug discovery development, pharmacogenomics and toxicogenomics. Next-generation PCR enzymes have been engineered to suit the specific requirements of these varied applications.
Intensifying price pressures due to increased competition presents a major challenge to market expansion. The cost of the PCR reagents is a major concern, especially when research is being carried out in an academic laboratory. Due to the cost issue, researchers prefer the use of home-brewed reagents rather than purchasing reagents that are at the high end.
The requirement of licenses is stifling the entry of new entrants into in vitro diagnostics. This situation threatens to dampen revenue growth.
"The key technologies are patent protected, which prevents the free growth of the market," explains Ravishankar. "As the Tier 1 participants have already acquired patents, new participants have to be creative to expand their usage in terms of improved speed, processing and robustness, resulting in consistency of high amplification efficiency required for accurate relative quantification, regardless of amplicon length or complexity."
Companies that fail to address the issue of pricing at the appropriate time, stand to lose their competitive advantage. Many companies have entered into alliances with thermal cycler manufacturers and are using this strategy to market their brands.
If you are interested in more information on this study, please send an email with your contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]frost.com.
European PCR Reagent Market for Research Applications and Clinical Diagnostics is part of the Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European HIV/AIDS and Hepatitis B/C Molecular Diagnostics Market and European Point of Care (POC) Infectious Disease Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
European PCR Reagent Market for Research Applications and Clinical Diagnostics / M6DD